Balyasny Asset Management
MREO

Balyasny Asset Management’s Mereo BioPharma MREO Stock Holding History

Balyasny Asset Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,280,275
Closed -$533K – 3281
2025
Q4 		$533K Buy
+1,280,275
New +$2.44M ﹤0.01% 2499
2022
Q4 		– Sell
-19,211
Closed -$17K – 3055
2022
Q3 		$17K Buy
+19,211
New +$23.5K ﹤0.01% 2597

Other funds holding MREO

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $12.7B AUM 17.31% 1-Year Est. Return

Balyasny Asset Management's MREO Position: Q1 2026 in Review

Balyasny Asset Management sold out of Mereo BioPharma (MREO) in Q1 2026, closing a stake of 1,280,275 shares — an estimated $533K sold.

Balyasny Asset Management first reported a position in MREO in Q3 2022 and held it in 2 quarters. The position peaked at $533K in Q4 2025. 63 funds tracked by Wall St. Rank hold MREO as of Q1 2026.

  • Balyasny Asset Management reported no remaining Mereo BioPharma position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 1,280,275 Mereo BioPharma shares in Q1 2026, an estimated $533K.
  • Balyasny Asset Management first reported a position in Mereo BioPharma in Q3 2022 and held it in 2 quarters.
  • Balyasny Asset Management's Mereo BioPharma position peaked at $533K in Q4 2025.
  • 63 funds tracked by Wall St. Rank held Mereo BioPharma as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.